Dr Reddy#39;s Labs trades lower despite robust Q3 as Credit Suisse flags EBITDA worries
- Hot Stocks
admin
- 0
- 1 minute read
According to Credit Suisse, Suboxone still constitutes about 7 percent of Dr Reddy#39;s Labs#39; base EBITDA, and the entry of Apotex could potentially impact 40 percent of DRL#39;s EBITDA from Suboxone or 3 percent of consolidated EBITDA.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2021524839-bcee0315df4d4381a522f697afb6b0e0.jpg "<div>The 'Rule of 10' For Finding the Next Stock Market Winners</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1577052076-7119b9f1fd184b49860aa96f3a928774.jpg "How Much Mortgage Can I Afford?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-486294093-d27f5435fd6b42d5ad8cbce6fb6a80a0.jpg "<div>Warren Buffett's Worst Deal Ever Cost .87B—Here's What You Can Learn From It</div>")
:max_bytes(150000):strip_icc():format(jpeg)/senioryoga-58cfb4203df78c3c4fe0f9b2.jpg "Can Snowbirds Have 2 Reverse Mortgages?")